Association between cytokines and psychiatric symptoms in chronic fatigue syndrome and healthy controls.
Groven, Nina, Fors, Egil A, Iversen, Valentina C et al. · Nordic journal of psychiatry · 2018 · DOI
Quick Summary
This study looked at immune system markers called cytokines in people with ME/CFS compared to healthy people, and how these markers related to mood and anxiety symptoms. Researchers found that people with ME/CFS had slightly higher levels of one immune marker (TNF-α) and discovered different patterns of how immune markers connected to psychiatric symptoms in ME/CFS patients versus healthy controls. The findings suggest that immune system activity may work differently in ME/CFS, which could help explain some symptoms and guide future treatments.
Why It Matters
Understanding how immune markers differ between ME/CFS patients and healthy people—and how they relate to psychiatric symptoms—could help identify biological mechanisms underlying ME/CFS and potentially guide new treatment strategies. This research suggests that immune dysfunction in ME/CFS may not follow the same patterns as in other conditions, emphasizing the need for ME/CFS-specific research.
Observed Findings
TNF-α levels in CFS/ME patients were elevated compared to controls, approaching but not reaching statistical significance (p=0.056)
TNF-α correlated with depressive symptoms (HADS) in healthy controls but not in CFS/ME patients
IL-10 showed significant correlation with psychoticism in both CFS/ME patients and healthy controls
IL-10 correlated with somatization (SCL-90-R) only in the CFS/ME group, not in controls
Inferred Conclusions
Immune activity patterns in CFS/ME patients differ from healthy controls, suggesting distinct biological mechanisms in the disease
The relationship between specific cytokines and psychiatric symptoms differs between CFS/ME and healthy populations, indicating that psychiatric symptoms in ME/CFS may have different biological underpinnings
These immune-psychiatric associations point to potential therapeutic targets and support further investigation of immune dysregulation in ME/CFS
Remaining Questions
Do these cytokine differences and immune-psychiatric correlations persist over time, or do they change as disease severity fluctuates?
How do these findings relate to ME/CFS severity, symptom subtypes, and patient subgroups defined by different clinical features?
What This Study Does Not Prove
This study does not prove that cytokine differences cause psychiatric symptoms or vice versa—it only shows they are associated. The small sample size and cross-sectional design prevent conclusions about whether immune changes drive symptom development or how they change over time. The findings cannot be generalized to all ME/CFS patients, particularly those with different symptom profiles.